Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. May 7, 2007; 13(17): 2427-2435
Published online May 7, 2007. doi: 10.3748/wjg.v13.i17.2427
Published online May 7, 2007. doi: 10.3748/wjg.v13.i17.2427
Virus | Animal tested | Infection | Original reference | |
HCV | Non human primates | Chimpanzee | Yes | Alter et al[2] 1978 |
Marmoset | Yes | Feinstone et al[71] 1981 | ||
Cottontop tamarin | No | Garson et al[72] 1997 | ||
Cynomoglus monkey | No | |||
Rhesus monkey | No | |||
Green monkey | No | |||
Japanese monkey | No | Abe et al[73] 1993 | ||
Doguera baboon | No | |||
Chacma baboon | No | Sithebe et al[74] 2002 | ||
Scandentia | Tupaia | Yes | Xie et al[75] 1998 | |
Rodents | uPA/SCID mice | Yes | Mercer et al[26] 2001 | |
Trimera mice | Yes | Galun et al[10] 1995 | ||
Rat | Yes | Wu et al[8] 2005 | ||
Woodchuck | No | Abe et al[73] 1993 |
Rodent models | Humanization | Viremia | Duration of viral infection | Comments | Publications |
uPA/SCID mice | Human hepatocyte transplantation | 1 × 104 to 8 × 107 copies/mL | Up to 9 mo with maximum viremia as from one month | High viremia | |
Variability of primary human hepatocytes | Mercer et al[26] 2001 | ||||
Meuleman et al[22] 2005 | |||||
Immunosuppressed mice | Kneteman et al[29] 2006 | ||||
Trimera mice | Xenograft of human liver tissue | Around 7 × 104 copies/mL | Around one month with peak viremia at 18 d | Low viremia | |
Variability of human liver tissues | Ilan et al[12] 2002 | ||||
Immunosuppressed mice | Eren et al[11] 2006 | ||||
Rat | Immunotolerization and transplantation of a human hepatoma cell line | 1-2 × 104 copies/mL | Minimum 4 mo with peak viremia at 3 mo | Low viremia | |
Transplantation of a hepatoma cell line | Wu et al[8] 2005 | ||||
Immunocompetent rat |
Viral protein | Original reference of the transgenic mouse | Mouse strain | Promoter | Comments | References |
Core | Moriya et al[42] 1997 | C57BL/6 | HBV | Steatosis | Moriya et al[40] 1998 |
HCC | Moriya et al[42] 1997 | ||||
Oxidative stress | Moriya et al[41] 2001 | ||||
Increased concentration of monounsaturated fatty acids | Moriya et al[37] 2001 | ||||
Inhibition of microsomal triglyceride transfer protein activity and VLDL secretion. | Perlemuter et al[38] 2002 | ||||
Alcohol and core protein increase lipid peroxidation | Perlemuter et al[39] 2003 | ||||
Alteration of intrahepatic cytokine expression and AP-1 activation | Tsutsumi et al[45] 2002 | ||||
Interaction with retinoid X receptor alpha | Tsutsumi et al[43] 2002 | ||||
Cooperation with ethanol activation of MAPK | Tsutsumi et al[44] 2003 | ||||
Insulin resistance | Shintani et al[34] 2004 | ||||
Koike et al[33] 2006 | |||||
Modulation of interferon pathway (Inhibition of SOCS-1 expression) | Miyoshi et al[47] 2005 | ||||
ER stress, apoptosis | Benali-Furet et al[78] 2005 | ||||
Core | Honda et al[52] 2000 | C57BL/6 | HBV | Modulated sensitivity to Fas-mediated apoptosis | Honda et al[52] 2000 |
Insulin resistance via down-regulation hepatic IRS1 and 2 | Kawaguchi et al[35] 2004 | ||||
Constitutive activation of STAT3, implication in HCC | Yoshida et al[46] 2002 | ||||
Core | Pasquinelli et al[50] 1997 | C57BL/6 | Major urinary protein | No liver disease | Pasquinelli et al[50] 1997 |
Core (Korean wt and mutants) | Wang et al[79] 2004 | C57BL/6J | HBV | Cell dysplasia for S99Q core mutant | Wang et al[79] 2004 |
Core (in T cell) | Soguero et al[53] 2002 | C57BL/6 | CD2 | Increased Fas-mediated apoptosis and liver infiltration of peripheral T cells | Soguero et al[53] 2002 |
Double Tg core X TCR | Cruise et al[55] 2005 | C57BL/6 × DO11.10 (H-2d) | Increased Fas ligand expression of CD4+ T cells associated with liver inflammation | Cruise et al[55] 2005 | |
Role of CXCR3 ligands via Fas induction, during the inflammatory response | Cruise et al[54] 2006 | ||||
Core | Ishikawa et al[48] 2003 | C57BL/6N | serum amyloid | Malignant lymphoma and Hepatocellular adenoma in old mice | Ishikawa et al[48] 2003 |
Core | Kato et al[49] 2003 | C57BL/6 | serum amyloid P | Adenoma and HCC development in transgenic mice following repeated CCl4 administrations. | Kato et al[49] 2003 |
Core Core-E1-E2 | Kamegaya et al[51] 2005 | FVB × C57BL/6 | Albumin | After DEN treatment, core-E1-E2 mice develop tumors with a larger size than core mice (diminution of apoptotic index) | Kamegaya et al[51] 2005 |
Core-E1-E2-p7 | Lerat et al[62] 2002 | C57BL/6 | Albumin | Steatosis | Lerat et al[62] 2002 |
HCC (rare) | |||||
Sensitivity to oxidative stress | Okuda et al[80] 2002 | ||||
Core-E1-E2-p7 | Korenaga et al[81] 2005 | C57BL/6J | Albumin | Increase in ROS production by mitochondrial electron transport complex I | Korenaga et al[81] 2005 |
Core-E1-E2 | Kawamura et al[82] 1997 | FVB | Albumin or major urinary protein | No liver disease | Kawamura et al[82] 1997 |
Core-E1-E2 | Honda et al[56] 1999 | C57BL/6 | H2-Kd | Sensitivity to anti-fas administration | Honda et al[56] 1999 |
Core-E1-E2 | Naas et al[57] 2005 | C57BL/6 | CMV | Steatosis. | Naas et al[57] 2005 |
Acceleration of liver and lymphoid tumor development | |||||
Core-E1-E2-NS2 | Wakita et al[59] 1998 | Balb/C | Cre/Lox system (CAG promoter) | Hepatitis injury associated with HCV-specific CTL response | Wakita et al[59] 1998 Wakita et al[58] 2000 |
Suppression of Fas-mediated cell death | Machida et al[83] 2001 | ||||
HCV-specific CD8+ CTLs specifically induce liver injury | Takaku et al[62] 2003 | ||||
E1-E2 | Koike et al[63] 1995 | CD1 | HBV | No liver disease | Koike et al[63] 1995 |
Expression in salivary glands | |||||
Exocrinopathy resembling Sjogren syndrome | Koike et al[84] 1997 | ||||
E2 | Pasquinelli et al[50] 1997 | C57BL/6 | Albumin | No liver disease | Pasquinelli et al[50] 1997 |
NS3-NS4A | Frelin et al[64] 2006 | C57BL/6 | Major urinary protein | No liver disease. | Frelin et al[64] 2006 |
Alteration of hepatic immune cell subsets. | |||||
Reduced sensitivity to TNF alpha mediated liver disease. | |||||
NS5 | Majumder et al[65] 2002 | FVB | ApoE | No liver disease | Majumder et al[65] 2002 |
Protection against TNF alpha mediated liver disease (inhibition of NF-kappaB activation) | Majumder et al[66] 2003 | ||||
Full polyprotein | Alonzi et al[60] 2004 | C57BL/6 | Alpha1 antitrypsin | Steatosis | Alonzi et al[60] 2004 |
Blindenbacher et al[67] 2003 | T cell infiltrate | ||||
Inhibition of IFN alpha-induced signaling | Blindenbacher et al[67] 2003 | ||||
Increased expression of protein phosphatase 2A | Duong et al[68] 2004 | ||||
Full polyprotein | Lerat et al[62] 2002 | C57BL/6 | Albumin | Hepatic steatosis, HCC | Lerat et al[62] 2002 |
Impairment of intrahepatic immune response (absence of elimination of adenovirus-infected hepatocytes) | Disson et al[85] 2004 | ||||
Down-regulation of pro-apoptotic CIDE-B protein in adenovirus-infected transgenic mice | Erdtmann et al[86] 2003 | ||||
Iron overload induces increase the risk of HCC (mitochondrial injury) | Furutani et al[87] 2006 |
- Citation: Kremsdorf D, Brezillon N. New animal models for hepatitis C viral infection and pathogenesis studies. World J Gastroenterol 2007; 13(17): 2427-2435
- URL: https://www.wjgnet.com/1007-9327/full/v13/i17/2427.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i17.2427